story of the week
Overall Survival With Palbociclib Plus Endocrine Therapy vs Capecitabine in Postmenopausal Patients With HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
Eur. J. Cancer 2022 Jun 01;168(xx)12-24, M Martín, C Zielinski, M Ruiz-Borrego, E Carrasco, EM Ciruelos, M Muñoz, B Bermejo, M Margelí, T Csöszi, A Antón, N Turner, MI Casas, S Morales, E Alba, L Calvo, J de la Haba-Rodríguez, M Ramos, L Murillo, A Santaballa, JL Alonso-Romero, P Sánchez-Rovira, M Corsaro, X Huang, C Thallinger, Z Kahan, M Gil-GilFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.